For how we live.
A 100-child randomized trial in Uganda found a cheap supplement lowered infection rates on top of standard hydroxyurea therapy — though the authors say it needs a bigger trial before it changes practice.
Most women have a recurrence within a year of standard treatment. A 2025 trial stopped early once treating a woman alone proved inferior to treating her and her male partner together.
Weekly fluconazole kept most women free of thrush during treatment, yet by 12 months, six months after stopping, the advantage had narrowed sharply. A newer drug shows more durable suppression.
In the 240-woman ALTAR trial, methenamine hippurate was non-inferior to standard low-dose antibiotic prophylaxis over a year. Most other non-antibiotic prevention strategies still rest on weak evidence.
In 59 facilities across Malawi and Uganda where 431,394 women gave birth, the APT-Sepsis programme reduced infection-related death, near-miss events and severe illness from 1.9% to 1.4%.